Lung Cancer Clinical Trials & Research at St. Joseph Health Medical Group
The two main types of lung cancer are non-small cell lung cancer and small
cell lung cancer. The types are based on the way the cells look under
a microscope. Non-small cell lung cancer is much more common than small
cell lung cancer. Tobacco smoking is the most common cause of lung cancer.
St. Joseph Health Medical Group is currently enrolling patients for the
following lung cancer clinical trials:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
A Phase III, randomized, double-blind, placebo-controlled, multicenter,
international study of osimertinib as maintenance therapy in patients
with locally advanced, unresectable EGFR mutation-positive Non-Small Cell
Lung Cancer (Stage III) whose disease has not progressed following definitive
platinum-based chemoradiation therapy (LAURA)
Treatment agent: Osimertinib
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03521154
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination
with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small
Cell Lung Cancer (G1T38)
Treatment agent: G1T38 (CDK4/6 inhibitor) +/- Osimertinib
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03455829
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy
with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated
Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants
(KEYNOTE-789)
Treatment agent: Carboplatin/cisplatin + pemetrexed +/- pembrolizumab
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03515837
Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs.
Pembrolizumab Alone as First-line Therapy in Patients with Metastatic
Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (CYPRESS 1)
Treatment agent: Pembrolizumab +/- AM0010 (interleukin 10)
PI:
Ian Anderson, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT02387216
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy
+/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants
with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Treatment agent: Platinum doublet chemo +/- pembrolizumab
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03425643
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum
Doublet Chemotherapy and Radiotherapy for Participants with Unresectable,
Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
Treatment agent: Platinum doublet chemo + radiotherapy + pembrolizumab
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03631784
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab
Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy
in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
Treatment agent: Rovalpituzumab (DLL3 protein ADC)
PI:
Ian Anderson, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT03033511